Pharmaxis Ltd operates within the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Pharmaxis Ltd with three other companies in this sector in AUSTRALIA : Mesoblast Ltd (2021 sales of 9.98 million Australian Dollars [US$7.23 million] of which 100% was Adult Stem Cell Development), Idt Australia Limited. (16.93 million Australian Dollars [US$12.27 million] ), and Kazia Therapeutics Ltd (15.22 million Australian Dollars [US$11.03 million] of which 100% was Pharmacetical research and development b).

Sales Analysis. During the year ended June of 2021, sales at Pharmaxis Ltd were A$22.85 million (US$16.55 million). This is an increase of 82.0% versus 2020, when the company's sales were A$12.55 million. Sales of Mannitol saw an increase that was more than double the company's growth rate: sales were up 221.6% in 2021, from A$7.05 million to A$22.67 million. Not all segments of Pharmaxis Ltd experienced an increase in sales in 2021: sales of New Drug Development fell 89.5% to A$544,000.00 . Pharmaxis Ltd also experienced decreases in sales in Corporate (down 9.4% to A$416,000.00 ) .